Breakthroughs Blog: Vaccines

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. Sanofi Pasteur’s announcement that it will cease work on its Zika vaccine candidate has raised concerns about the future of Zika vaccine development. While the World Health Organization has reported 40 Zika vaccine candidates in development, with six candidates in phase 1 clinical trials, Sanofi was the only major pharmaceutical company working on a vaccine against the virus. Its exit from this space raises questions about who will fund clinical development if these candidates show further promise. Additionally, many unanswered questions remain about the virus’s epidemiology and the target population for a vaccine. While the number of Zika cases is now falling, Zika epidemics will likely reoccur in the future. Because of this risk, developing an effective and low-cost Zika vaccine must remain a priority. Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA) have formed a partnership to develop vaccines and drugs to protect against pandemic influenza. Among its projects, the partnership is seeking to develop a “universal” flu vaccine that protects against all or most influenza strains. This collaborative effort highlights a larger trend in partnerships between the private sector, the US government, and nonprofits to develop vaccines and technologies against emerging health threats for which there is currently limited commercial market. Pakistan has launched its first nationwide vaccination drive for polio, aiming to immunize over 37 million children. Pakistan is one of just three countries where polio cases remain, so this nationwide drive is an important step toward eradication. While polio still remains endemic in Pakistan, the number of cases has reduced dramatically in recent years from 306 cases in 2014 to just 4 today. Pakistan has experienced obstacles in its attempts to eradicate the virus, which include efforts by extremists to target immunization campaigns.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.  Researchers at MIT are working to create an all-inclusive vaccine for infants that can protect against diphtheria, whooping cough, polio, measles, meningitis A, B, and C, and more. The researchers have designed a promising micro-particle that could combine all of these vaccines into one single shot. The shot has not yet been tested on humans, though results were promising in a trial on mice. If this micro-particle proves effective and safe in human trials, this all-inclusive vaccine will be useful for infants in developing countries—as reducing the  number of vaccines necessary for infants in low-resource settings means fewer clinic visits. Mobile technology has the potential to help save the lives of newborns and their mothers in Tanzania. Researchers and phone developers are hoping to reduce rates of maternal mortality by launching a new service called “Text to Treatment” that uses toll-free texting to provide women with information that facilitates access to treatment centers. For instance, this service allows users to send money for travel to free clinics. Similarly, the “Mobilising Maternal Health” program also aims to provide better access to health care services by connecting women to transportation services, such as ambulance taxis and other travel to free clinics. Both of these programs have saved lives, with a 40 percent increase in female patients visiting treatment centers due to the “Text to Treatment” service and 30 percent reduction in maternal deaths due to the “Mobilising Maternal Health” program. These services have the potential to help bridge the rural-urban divide that impacts access to timely, high-quality health care for new mothers. Researchers at the University of Alberta, Canada have discovered the malaria parasite uses tagged carbohydrates to avoid detection and continue the spread of the disease in humans—especially in the liver. The researchers believe if treatments can be improved to account for the tagged carbohydrates, then these solutions may weaken the parasite to the point where it cannot survive within the host. They also believe these findings may help improve malaria vaccine design. Malaria remains one of the leading killers in the developing world, with about 650,000 annual deaths due to the disease.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.Sanofi, a major vaccine developer, ceased their Zika vaccine program, highlighting how difficult it is to develop an effective vaccine for Zika. The US Biomedical Advanced Research and Development Authority reduced funding to Sanofi for the vaccine program last month, and Sanofi announced in early September it will no longer seek funding to continue its vaccine research. Smaller companies are in clinical stages of testing different Zika vaccine candidates, but Sanofi was the first major US pharmaceutical company to begin research on a potential vaccine for the virus. A female Culex quinquefasciatus mosquito (CDC/ James Gathany)The Infectious Diseases Data Observatory, a research observatory based out of the University of Oxford in the United Kingdom, is developing a data-sharing platform to compile and share Ebola data to aid in the response to future outbreaks. Researchers are seeking to engage local African leaders in the platform's creation to provide cultural context and ensure the resulting system improves the capacity of African researchers to conduct research in outbreak scenarios. Organizers agree that developing the platform now—during a period of no active outbreaks—is critically important, as having the platform available for aid workers and medical professionals before the next Ebola outbreak may aid in saving lives. A new, low-cost tool has been introduced in disadvantaged areas to treat newborn asphyxia. Newborn asphyxia is highly prevalent in low-resource settings, with about 20 percent of all newborn deaths in India caused by the condition. Therapeutic hypothermia—which reduces an infants body temperature—is a common treatment, but hypothermia-inducing machines are typically too costly for low-resource settings. Dr. Niranjan Thomas of Vellore, India created the MiraCradle, a fast-acting, low-cost device made of several phase changing materials—substances that absorb and release thermal energy—that is used as a regulation agent to keep a newborn hypothermic. The MiraCradle is currently being used in about 125 hospitals throughout India and South Africa.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. The only existing tuberculosis (TB) vaccine—the bacille Calmette-Guerin (BCG) vaccine—has proven to be more effective than previously thought, delivering protection against the disease for around 20 years. The London School of Hygiene and Tropical Medicine led a study that found half of those individuals who were given the vaccine at ages 12 or 13 were protected against TB for at least 20 years. The vaccine was thought to deliver protection for only 10 to 15 years. These findings strenthen the case for administering BCG to children in low- and middle-income countries with high TB rates. The Tanzanian government has announced that in 2018 the country will begin using Zipline drones to deliver essential medical technologies to citizens in the capital city of Dodoma. The drone service can deliver everyday goods like food, but can also deliver live-saving medicines and vaccines, and contraceptives like condoms. Technology in low-resource and rural parts of the world has been used in the past to help diagnose and track diseases, but these technologies have proven challenging to deliver due to rugged terrain or geographic isolation. The Zipline drones are the first of their kind and can deliver products within a 50-mile radius. The Tanzanian Ministry of Health is working to add three more drone locations within the nation. The University of North Carolina Chapel Hill is studying the efficacy of a rapid diagnostic tool for malaria in very rural areas of Uganda. Researchers testing the low-cost tool in these areas and found that it could perform diagnoses with high specificity and sensitivity for both uncomplicated and severe malaria. This level of accuracy in diagnosis may allow health professionals to prioritize treatment for cases that may be more life threatening than others. Accurately diagnosing children who contract a severe form of malaria makes it possible to prioritize cases and potentially save lives.